BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94. [PMID: 31588679 DOI: 10.1002/cam4.2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94. [PMID: 31588679 DOI: 10.1002/cam4.2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Yang K, Choi C, Cho H, Ahn WG, Kim SY, Shin SW, Kim Y, Jang T, Lee N, Park HC. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics 2021;13:1811. [PMID: 34834226 DOI: 10.3390/pharmaceutics13111811] [Reference Citation Analysis]
3 Jin S, Tan S, Peng W, Jiang Y, Luo C. Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: a systematic review and meta-analysis. World J Surg Oncol 2020;18:199. [PMID: 32787883 DOI: 10.1186/s12957-020-01966-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Reference Citation Analysis]
5 Yadav P, Mimansa, Munawara R, Kapoor K, Chaturvedi S, Kailasam K, Biswas SK, Bahadur D, Srivastava R, Mishra AK, Shanavas A. Nontoxic In Vivo Clearable Nanoparticle Clusters for Theranostic Applications. ACS Biomater Sci Eng 2022;8:2053-65. [PMID: 35416030 DOI: 10.1021/acsbiomaterials.1c01579] [Reference Citation Analysis]
6 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
7 Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Front Oncol 2022;12:879454. [DOI: 10.3389/fonc.2022.879454] [Reference Citation Analysis]
8 Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol 2021;27:144-56. [PMID: 33280350 DOI: 10.3350/cmh.2020.0095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Su K, Guo L, He K, Rao M, Zhang J, Yang X, Huang W, Gu T, Xu K, Liu Y, Wang J, Chen J, Wu Z, Hu L, Zeng H, Li H, Tong J, Li X, Yang Y, Liu H, Xu Y, Tan Z, Tang X, Feng X, Chen S, Yang B, Jin H, Zhu L, Li B, Han Y. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. Front Oncol 2022;12:873830. [DOI: 10.3389/fonc.2022.873830] [Reference Citation Analysis]
10 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
11 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
12 Dong D, Zhu X, Wang H, Li L, Wan M, Li S, Zhang Y, Geng J, Li Y, Wang W. Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy. J Med Imaging Radiat Oncol 2022. [PMID: 35243796 DOI: 10.1111/1754-9485.13398] [Reference Citation Analysis]
13 Kim N, Yu JI, Park HC, Yoo GS, Choi C, Hong JY, Lim HY, Lee J, Choi MS, Lee JE, Kim K. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2021;70:1593-603. [PMID: 33231725 DOI: 10.1007/s00262-020-02794-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Reference Citation Analysis]
15 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
16 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist 2021;26:e1036-49. [PMID: 33314549 DOI: 10.1002/onco.13638] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
18 Kang C, Jeong SY, Song SY, Choi EK. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiat Oncol J 2020;38:1-10. [PMID: 32229803 DOI: 10.3857/roj.2019.00640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
19 Li D, Li K, Zhang W, Yang K, Mu D, Jiang G, Shi R, Ke D. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma. Front Immunol 2022;13:918140. [DOI: 10.3389/fimmu.2022.918140] [Reference Citation Analysis]